A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
Latest Information Update: 08 Sep 2024
At a glance
- Drugs GS 030 (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; First in man
- Acronyms PIONEER
- Sponsors GenSight Biologics
- 20 Jun 2024 According to a Gensight Biologics media release, follow-up of GS030 (an optogenetic treatment candidate for Retinitis Pigmentosa) patients treated in the PIONEER Phase I/II trial is ongoing, with intermediate results from PIONEER expected in 2025.
- 13 Feb 2023 Results published in the Gensight Biologics media release.
- 13 Feb 2023 According to Gensight Biologics media release, extension cohort patients are currently being recruited.